ArticleBMC urology2025
LINC00332 as a potential diagnostic marker for the low-grade tumors in renal cell carcinoma patients.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) ranks as a frequent malignancy among urological cancers worldwide and has a positive prognosis during the initial tumor phases. Since, metastatic RCC patients have poor prognosis, it is essential to examine the molecular biology of RCC progression in order to implement effective diagnostic and therapeutic markers for these patients. Long non-coding RNAs (lncRNAs) have essential roles in modulating molecular processes during RCC progression. Therefore, we evaluated the probable correlations between LINC00332 expression levels and clinicopathological features of RCC patients to suggest that as a tumor marker.
methodsFifty newly obtained samples of RCC tumor tissues and their corresponding normal margins were gathered for examining the expression levels of LINC00332 and any potential correlations with the clinicopathological characteristics of RCC patients. Real-time PCR using the SYBR green method was applied to assess the levels of LINC00332 expressions in RCC patients.
resultsThere were significant reduced levels of LINC00332 expressions in high-grade compared with low-grade tumors among male RCC patients (p = 0.048). There was also significant reduced LINC00332 expression in high-grade compared with low-grade tumors among RCC patients younger than 60 years old (p = 0.007).
conclusionsLINC00332 expression levels were significantly lower in high-grade tumors compared to low-grade tumors in male RCC patients and in patients under 60 years old. Therefore, LINC00332 can be proposed as a diagnostic marker for the low-grade tumors before the age of 60 after additional tests in serum samples of RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.